# EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome

> **NCT00056199** · PHASE1 · COMPLETED · sponsor: **National Eye Institute (NEI)** · enrollment: 5 (—)

## Conditions studied

- Hippel-Lindau Disease

## Interventions

- **DRUG:** EYE001

## Key facts

- **NCT ID:** NCT00056199
- **Lead sponsor:** National Eye Institute (NEI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 5 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056199, "EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00056199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*